You just read:

Mast Therapeutics Announces Initiation Of Patient Enrollment In Additional Phase 2 Study Of AIR001 For The Treatment Of Heart Failure With Preserved Ejection Fraction

News provided by

Mast Therapeutics, Inc.

Dec 06, 2016, 09:00 ET